|
|
Profile
|
Delegates :
Toshiro Morohoshi, Ph.D. |
|
Incorporated :
January 15 , 2008 |
Paid in Capital :
60 Million yen |
Employees :
3 人 |
Address :
Life Science Building 7 1-9-10 Nihonbashi Horidomecho, Chuo-ku, Tokyo TOKYO
〒103-0012
|
TEL/FAX :
03-5203-0715 / |
URL：
https://www.c-pa.jp/encompanyprofile.html |
Attachment :
|
Mission/Background :
SANSHO is a bio-venture company specializing in the development of pharmaceuticals based on Lipidology using small-molecule compounds derived from natural products. |
|
Technology & Business
|
In recent years, the relationship between lipid metabolites and diseases (Lipidology) has been rapidly developing due to the dramatic advances in mass spectrometry and genetic research. Lysophosphatidic acid (LPA), one of lysolipids, has also attracted attention for its involvement in cancer cell migration and fibrosis through the discovery of specific receptors (LPA1-6).
Cyclic phosphatidic acid (cPA), which is produced at the same time as LPA and cyclized at the polar end of LPA, has been reported to inhibit cancer cell invasion, analgesia, arthritis relief, and neuronal cell death.
We found a derivative of cPA, 2-carba-cPA (2ccPA), and it was stable and highly active. 2ccPA is currently in Phase-II clinical trials overseas for knee osteoarthritis, and a clinical trial for idiopathic pulmonary fibrosis is planned to begin within 2025.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
SSO-001(Knee osteoarthritis treatment drug)
|
Phase2
|
SSO-001 may act as a disease-modifying drug and relieves OA associated symptoms, completed Phase IIa clinical study.
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
SSI-002 (Drugs for treating Idiopathic Pulmonary Fibrosis(IPF))
|
Preclinical
|
SSI-002 is a promising therapeutic candidate for pulmonary fibrosis, planned Phase I clinical study in 2026.
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
SSG-003
|
Preclinical
|
Indication: glaucoma
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
SSD-004 (Systemic sclerosis treatment drug):
|
Preclinical
|
SSD-004 could be a novel strategy for the treatment of SSc.
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
SSH-005 (Congenital hypotrichosis treatment drug)
|
Preclinical
|
SSH-005 could be a new treatment option for congenital hypotrichosis.
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
|
Highlights
|
April 2024\tReported results of a clinical trial for Knee osteoarthritis at OARSI* (Vienna, Austria)
May 2024\tReported results of a non-clinical pulmonary fibrosis study at ATS** (San Diego, USA).
March 2025\tPhase 2a clinical trial of 2ccPA completed in Taiwan (indication: Knee osteoarthritis)
*The Osteoarthritis Research Society International 
**American Thoracic Society International Conference
|
|
Alliance strategy
|
SSO-001: Acquiring license partners
Other pipelines: Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
|
|